Rare cutaneous reactions after ChAdOx1 (Oxford-AstraZeneca) vaccine: 12 case series from Brazil

Editor

Brazil is one of the most affected countries by COVID-19 pandemic with 22,2mi confirmed cases and 616,000 deaths until 12/10/21. Population is 68.1% fully vaccinated, and 317mi doses have been administered. Recombinant ChAdOx1 (Oxford-AstraZeneca) is the most applied vaccine. Cutaneous reactions after ChAdOx1 vaccine are mainly injection-site reactions, acute urticaria and morbilliform rash. We report 12 patients with cutaneous reactions after ChAdOx1 vaccine, nine of which as rare forms.

Gender was equally distributed (six female, six male). Their median age was 52.3 years (range 27–85 years). Cutaneous reactions occurred mainly after ChAdOx1 vaccine first dose (nine patients), from 1 to 7 days after vaccine administration. Dermatologists saw all patients. Nine patients presented rare cutaneous reactions: three lichen planus, three purpura/vasculitis, two erythroderma and one fixed drug eruption (Fig. 1). Maculopapular eruption and urticaria accounts for the remaining three cases. Eleven patients were submitted to anatomopathological evaluation of cutaneous lesions (Table 1).

Lichen planus after ChAdOx1 vaccination was observed in three patients. One patient had history of lichen planus, and curiously reactivation occurred exactly in previous sites of the disease. Bullous lichen planus was observed in one case. Due to severity of cutaneous lesions and its symptoms, patient was hospitalized. SARS-CoV-2 is known as a possible trigger for lichen planus. One case of lichen planus arising after mRNA BNT162b2 (Pfizer-BioNTech) was related. Vaccines may upregulate Th1 response, promote IL-2, TNFα and IFNγ elevation, which increase basal keratinocyte apoptosis presented in lichen planus. As far as the authors knows, these are the first cases of lichen planus after ChAdOx1 vaccine, and the only case of bullous lichen planus associated to SARS-CoV-2 vaccination.

Three patients presented with purpura. In two cases small vessel vasculitis was histologically confirmed – one associated with systemic symptoms (fever, arthralgia, mononeuritis) and one with severe cutaneous lesions such as vesicles and necrosis. In one case purpura was caused by idiopathic thrombocytopenic purpura (ITP). Vasculitis was observed in 0.7–2.9% after mRNA vaccine (Pfizer-BioNTech and Moderna) in a study that evaluated 414 patients with cutaneous reactions. No vasculitis was reported in the phase 2/3 clinical trial of Oxford-AstraZeneca vaccine. Only two published cases related vasculitis and IPT after ChAdOx1 vaccine.

Erythroderma was observed in two patients with no previous dermatosis or allergy history. Cutaneous lesions initiated after first and second doses, from 24–48 h postvaccine administration. Laboratorial workup was normal. Both were elderly, required systemic corticotherapy and presented a late (15–30 days) resolution. Erythroderma following mRNA vaccine was related, but there are no reports associating this condition to ChAdOx1 vaccine. Cutaneous reactions associated to COVID-19 vaccination are mostly mild to moderate, oligosymptomatic and self-limited. However, although rare, severe reactions may occur and demand specific treatment. Systemic corticosteroids therapy is controversial after vaccination. Our patients had no improvement with topical treatment and were sorely symptomatic. Systemic corticosteroids were prescribed as short as possible, as an exception treatment with suitable response.

One patient with HIV and antiretroviral therapy presented with fixed drug eruption 24 h after ChAdOx1 both first and second doses. Lesions were typical and histologically confirmed. HIV is known to increase drug reaction risk in 100–1000 times. Two cases of fixed drug eruption following ChAdOx1 and mRNA Moderna vaccines were published.

Cutaneous reactions after COVID-19 vaccination are not common and generally do not contraindicate vaccination cycle.

References

1. Humphreys H, Becker K, Dohmen PM et al. Staphylococcus aureus and surgical site infections: benefits of screening and decolonization before surgery. J Hosp Infect 2016; 94: 295–304.
2. Knox J, Uhlemann AC, Lowy FD. Staphylococcus aureus infections: transmission within households and the community. Trends Microbiol 2015; 23: 437–444.
3. Zhu F, Zhuang H, Ji S et al. Household transmission of community-associated methicillin-resistant Staphylococcus Aureus. Front Public Health 2021; 9: 658638.
4. Del Giudice P, Blanc V, De Rougemont A et al. Panton-Valentine leukocidin positive Staphylococcus aureus strains cause primary skin abscesses. Dermatology 2009; 219: 299–302.
5. Del Giudice P, Bes M, Hubiche T et al. Panton-valentine Leukocidin-positive staphylococcus aureus strains are associated with follicular skin infections. Dermatology 2011; 222: 167–170.
6. Servick K. COVID-19 measures also suppress flu—for now. Science 2021; 371: 224.
7. Oster Y, Michael-Gayego A, Rivkin M, Levinson L, Wolf DG, Nir-Paz R. Decreased prevalence rate of respiratory pathogens in hospitalized patients during the COVID-19 pandemic: possible role for public health containment measures? Clin Microbiol Infect 2020; 27: 811–812.
8. Subbarao S, Campbell H, Ribeiro S et al. Invasive meningococcal disease, 2011–2020, and impact of the COVID-19 pandemic, England. Emerg Infect Dis 2021; 27: 2495–2497.
9. McNell JC, Flores AR, Kaplan SL, Hulten KG. The indirect impact of the SARS-CoV-2 pandemic on invasive group a Streptococcus, Streptococcus Pneumoniae and Staphylococcus Aureus infections in Houston area children. Pediatr Infect Dis J 2021; 40: e313–e316.

DOI: 10.1111/jdv.18111
Vaccinations benefit supplants by far its inherent risks. Although rare, special forms of cutaneous reactions after COVID-19 vaccination must be recognized due to its severity, patients' impairment and particular management. As the widespread vaccination progress worldwide, these reactions might significantly increase.

Acknowledgement
The patients in this manuscript have given written informed consent to the publication of their case details.

Conflicts of interest
Authors have no conflicts of interest to declare.

Funding sources
A statement of all funding sources that supported the work. No funder supported this article.

Data availability statement
Data are openly available in a public repository that issues data-sets with DOIs.

C.A. Seque,1,2* M.M.S.S. Enokihara,3 M.M. Nascimento,1 A.M. Porro,1 J. Tomimori1,2
1Dermatology Department, Federal University of Sao Paulo, Sao Paulo, Brazil, 2Programa de Pós-Graduação em Medicina Translacional, Federal University of Sao Paulo, Sao Paulo, Brazil, 3Pathology Department, Federal University of Sao Paulo, Sao Paulo, Brazil
*Correspondence: C.A. Seque. E-mail: camilaseque@yahoo.com

References
1 https://coronavirus.jhu.edu/vaccines/international
2 Catalá A, Muñoz-Santos C, Galván-Casas C et al. Cutaneous reactions after SARS-CoV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases. Br J Dermatol 2022; 186: 142–152.
3 Díaz-Guimaraens B, Dominguez-Santas M, Suarez-Valle A et al. Annular lichen planus associated with coronavirus SARS-CoV-2 disease (COVID-19). Int J Dermatol 2021; 60: 246–247.

Figure 1 Cutaneous reactions after ChAdOx1 vaccine. Lichenoid eruption on the arm (a) and reactivated at lichen planus previous site (b). Bullous lichen planus (c). Purpura on the leg (d), with distal vesicles and necrosis (e). Erythroderma (f, g). Fixed drug eruption (h). Macular-papular eruption (i, j). Urticaria (k).
Table 1: Cutaneous reactions to ChAdOx1 vaccine: epidemiology, dermatologic manifestation, management and histology

| Patient | Age/SEX | Comorbidities | Doses | Onset post-vaccination | Duration of reaction | Dermatologic manifestation | Management | Histology |
|---------|---------|---------------|-------|------------------------|---------------------|---------------------------|------------|-----------|
| 1       | 55/M    | Diabetes      | 2nd   | 5 days                 | 30 days             | Lichen planus            | Topical corticoid, antihistamine | Dermatitis with superficial perivascular lymphocytic infiltrate |
| 2       | 30/M    | Lichen planus | 1st   | 5 days                 | 21 days             | Lichen planus reactivated at disease's previous sites | Topical corticoid, antihistamine | Lichenoid dermatitis with melanoderma |
| 3       | 63/F    | Hypertension, chronic renal disease | 1st   | 7 days                 | 14 days             | Bullous lichen planus     | Systemic corticoid | Lichenoid dermatitis with melanoderma |
| 4       | 62/M    | Hypertension, hypothyroidism | 1st   | 3 days                 | 14 days             | Purpura (idiopathic thrombocytopenic purpura) | Systemic corticoid | No available |
| 5       | 44/F    | Smoking       | 1st   | 2 days                 | 10 days             | Vasculitis with fever, arthralgia, mononeuritis | Systemic corticoid | Lymphocytic vasculitis |
| 6       | 64/F    | Hypertension, diabetes, heart failure | 2nd   | 7 days                 | 21 days             | Vasculitis with vesicles, necrosis | Systemic corticoid | Neutrophilic vasculitis |
| 7       | 66/M    | Hypertension  | 1st   | 2 days                 | 30 days             | Erythroderma              | Systemic corticoid | Spongy dermatitis |
| 8       | 85/M    | Chronic renal disease | 2nd   | 1 day                  | 14 days             | Erythroderma              | Systemic corticoid | Spongy dermatitis with superficial perivascular infiltrate |
| 9       | 27/M    | HIV           | 1st   | 1 day                  | 7 days              | Fixed drug eruption       | Topical corticoid, antihistamine | Interface dermatitis with melanoderma |
| 10      | 43/F    | None          | 1st   | 2 days                 | 12 days             | Macular eruption          | Expectant | Spongy dermatitis with superficial perivascular infiltrate |
| 11      | 43/F    | Atopic dermatitis | 1st   | 1 day                  | 7 days              | Papular eruption          | Expectant | Spongy dermatitis with superficial perivascular infiltrate |
| 12      | 46/F    | None          | 1st   | 2 days                 | 7 days              | Urticaria                | Antihistamine | Eosinophilic urticaria |

M, male; F, female; HIV, human immunodeficiency virus.

References:
4 Hiltun I, Sarriugarte J, Martínez-de-Esporroneda I et al. Lichen planus arising after COVID-19 vaccination. J Eur Acad Dermatol Venereol 2021; 35: e114–e115.
5 McMahon DE, Amerson E, Rosenbach M et al. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases. J Am Acad Dermatol 2021; 85: 46–55.
6 Guzmán-Pérez I, Puerta-Peña M, Falkenhain-López D et al. Small-vessel vasculitis following Oxford-AstraZeneca vaccination against SARS-CoV-2. J Eur Acad Dermatol Venereol 2021; 35: e741–e743.
7 Gambichler T, Boms S, Susok I et al. Cutaneous findings following COVID-19 vaccination: review of world literature and own experience. J Eur Acad Dermatol Venereol 2022; 36: 172–180.
8 Iwasawa O, Kamiya K, Okada H et al. A case of erythroderma with elevated serum immunoglobulin E and thymus and activation-regulated chemokine levels following coronavirus disease 2019 vaccination. J Dermatol 2022; 49: e117–e118.
9 Wantavornprasert K, Noppakun N, Klaewsongkram J et al. Generalized bullous fixed drug eruption after Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccination. Clin Exp Dermatol 2022; 47: 428–432.
10 Grieco T, Maddalena P, Semincola A et al. Cutaneous adverse reactions after COVID-19 vaccines in a cohort of 2740 Italian subjects: an observational study. Dermatol Ther 2021; 34: e15153.

De novo annular pustular psoriasis following mRNA COVID-19 vaccine

Editor

With the COVID-19 mass vaccination, many cutaneous reactions related to vaccines have been described, including flare-up or new-onset of common chronic inflammatory skin diseases like psoriasis. 1

We present here the case of a de novo annular pustular psoriasis (APP) following the mRNA vaccine.

A 64-year-old woman followed in our dermatologic department for a systemic lupus erythematosus (SLE) complained of a cutaneous eruption onset few days after the first dose of Pfizer-BioNTech BNT162b2 COVID-19 vaccine and worsened after the second dose. Prior to the newly onset eruption, LES cutaneous involvement was well-controlled by treatment with belimumab 200 mg once weekly, prednisone 12.5 mg per day and mycophenolate mofetil 1 g daily. Previous therapies included hydroxychloroquine, withdrawn due to pruritic rash and a single cycle of